Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.25M | 5.34M | 5.45M | 5.62M | 5.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.25M | 5.34M | 5.45M | 5.62M | 5.55M |
| Cost of Revenue | 2.18M | 2.10M | 2.08M | 2.01M | 1.65M |
| Gross Profit | 3.07M | 3.24M | 3.38M | 3.60M | 3.90M |
| SG&A Expenses | 2.42M | 2.43M | 2.76M | 2.64M | 2.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.59M | 4.53M | 4.84M | 4.66M | 4.63M |
| Operating Income | 658.50K | 805.00K | 614.30K | 957.40K | 917.10K |
| Income Before Tax | -5.64M | -5.34M | -3.98M | -3.31M | 1.44M |
| Income Tax Expenses | -155.20K | -162.20K | -167.80K | -49.40K | 41.50K |
| Earnings from Continuing Operations | -5.48 | -5.17 | -3.82 | -3.26 | 1.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -413.10K | -231.30K | -172.70K | -276.00K | -135.00K |
| Net Income | -5.90M | -5.40M | -3.99M | -3.54M | 1.26M |
| EBIT | 658.50K | 805.00K | 614.30K | 957.40K | 917.10K |
| EBITDA | 717.20K | 894.40K | 738.20K | 1.11M | 1.09M |
| EPS Basic | -0.04 | -0.03 | -0.02 | -0.02 | 0.01 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | 0.00 |
| EPS Diluted | -0.04 | -0.03 | -0.02 | -0.02 | 0.01 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | 0.00 |
| Average Basic Shares Outstanding | 649.02M | 649.02M | 649.02M | 649.02M | 649.02M |
| Average Diluted Shares Outstanding | 649.02M | 649.02M | 649.02M | 649.02M | 649.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |